Moderna's Global Material Planning Team is looking for an analytical and automation-focused Co-Op to modernize material planning across its global network. This role involves working at the intersection of supply chain, data, and automation, supporting the transformation of planning processes by developing automated tools, AI-enabled workflows, and scalable data solutions. The Co-Op will gain hands-on experience applying AI and automation within a global biotech supply chain from July 13th to December 11th, 2026.
Design and implement automated solutions to enhance material planning processes, reducing manual effort and accelerating decision-making.,Develop and deploy GPT-based tools and AI agents to assist planners with tasks like safety stock refresh analysis, lead time validation, inventory risk identification, and KPI commentary generation.,Build and automate weekly and monthly planning KPIs using tools such as Excel, Tableau, Power BI, Python, Chat GPT, or SAP data extracts.,Support the development of scalable methodologies for maintaining planning master data.,Analyze large datasets to identify trends, inefficiencies, and opportunities for improvement.,Collaborate cross-functionally with Procurement, Finance, and Site Planning to translate business needs into digital solutions.,Contribute to continuous improvement initiatives utilizing Lean and digital-first principles.,Lead a defined automation or AI pilot project from its conceptualization to implementation.
[object Object]
Bachelor's Degree or Master's Degree (currently enrolled)
Full time (July 13th-December 11th, 2026)
Must already hold work authorization in US and be able to maintain that status without future sponsorship.,Site-based, full-time presence at Moderna's site required; not eligible for remote work.,Employment contingent upon ability to access export-controlled information in accordance with U.S. law; only U.S. persons (citizens, permanent residents, asylees, or refugees) are eligible. Moderna is unable to sponsor non-U.S. persons for an export control license.
Moderna is a biotechnology company pioneering a new class of medicines made of messenger RNA (mRNA). The company's platform builds on continuous advances in basic and applied mRNA science, delivery technology and manufacturing, and has allowed the development of therapeutics and vaccines for infectious diseases, immuno-oncology, rare diseases, cardiovascular diseases and autoimmune diseases.
BerryMap uses cookies to provide essential features, analyze usage, and improve your experience. You can customize your preferences below.